MetaCap

Artiva Biotherapeutics (ARTV) vs Cabaletta Bio (CABA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Artiva Biotherapeutics (ARTV) has outperformed Cabaletta Bio (CABA) over the past year, gaining 20.8% versus a loss of 55.0%. Cabaletta Bio is the larger company by market cap ($201.9 million vs $186.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARTV+20.77%CABA-55.00%
+347%+136%-74%
Nov 21, 20251 yearNov 20, 2026
ARTV-68.50%CABA-86.80%
+38%-28%-94%
Jul 15, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARTV versus CABA key metrics
MetricARTVCABA
Share price$3.78$0.9361
Market cap$186.85M$201.94M
1-day change-1.31%-7.32%
YTD return-11.89%-57.26%
1-year return+20.77%-55.00%
5-year return—-91.93%
EPS (TTM)$-2.85$-1.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-83.86M$-167.86M
52-week high$14.53$4.23
52-week low$2.96$0.93
Distance from 52-week high-73.98%-77.87%
Analyst consensusbuystrong_buy
Avg. price target upside+448.94%+1155.21%
Average volume792.26K5.15M
Shares outstanding49.43M215.72M
Employees134154
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARTV has outperformed CABA by 75.8 percentage points over the past year.

About Artiva Biotherapeutics

ARTV stock →

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

About Cabaletta Bio

CABA stock →

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees

ARTV vs CABA FAQ

Which is bigger, Artiva Biotherapeutics or Cabaletta Bio?

Cabaletta Bio (CABA) is larger, with a market capitalization of $201.94M compared with $186.85M for Artiva Biotherapeutics (ARTV).

Which stock has performed better over the past year, ARTV or CABA?

ARTV returned +20.77% over the past 12 months, compared with -55.00% for CABA (price return, excluding dividends). Past performance does not predict future results.

Are Artiva Biotherapeutics and Cabaletta Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons